LOXO-195 expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing LOXO-195 clinical trial or have other considerations that prevent access to LOXO-195 through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers, including blood cancers, with a NTRK gene fusion who have previously received TRK inhibitor therapy